# Merck & Co., Inc. (MRK) — divestiture/asset_sale [announced]
Source: SEC API (secapi.ai) · situation sit_7f2228b2b65d1064798e · retrieved 2026-08-11T15:50:48.337Z

## Overview
Merck & Co., Inc. is a research-intensive biopharmaceutical company that develops and commercializes innovative medicines and vaccines across oncology, vaccines and infectious diseases, cardiometabolic and respiratory, immunology, and animal health.

Merck & Co., Inc. completed its acquisition of Terns Pharmaceuticals, Inc. for $6.8 billion. The acquisition added MK-4208, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor that has been granted Breakthrough Therapy designation by the FDA for the treatment of certain adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company recorded a $5.7 billion charge for the acquisition in the second quarter of 2026, with total charges of $2.31 per share included in both GAAP and non-GAAP loss per share for Q2 2026.

## Terms
- Counterparty: Terns Pharmaceuticals, Inc. · Deal value: $6.80B · Consideration: cash

## Key dates
- Announced 2026-08-04

## Timeline
- 2026-08-04 · 8-K (0001104659-26-090045): 8-K - Merck & Co., Inc. — *Merck & Co., Inc. is a research-intensive biopharmaceutical company that develops and commercializes innovative medicines and vaccines across oncology, vaccines and infectious diseases, cardiometabolic and respiratory, immunology, and animal health.* Merck & Co., Inc. completed its acquisition of Terns Pharmaceuticals, Inc. for $6.8 billion. The acquisition added MK-4208, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor that has been granted Breakthrough Therapy designation by the FDA for the treatment of certain adults with Philadelphia chromosome-positive chronic myeloid leukemia. The company recorded a $5.7 billion charge for the acquisition in the second quarter of 2026, with total charges of $2.31 per share included in both GAAP and non-GAAP loss per share for Q2 2026.
  https://www.sec.gov/Archives/edgar/data/310158/0001104659-26-090045.txt

## Citations
- 0001104659-26-090045 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926090045